Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo

被引：44

作者：

Deng, Wei ^{[1
,2
]}

Xu, Yanfeng ^{[1
,2
]}

Kong, Qi ^{[1
,2
]}

Xue, Jing ^{[1
,2
]}

Yu, Pin ^{[1
,2
]}

Liu, Jiangning ^{[1
,2
]}

Lv, Qi ^{[1
,2
]}

Li, Fengdi ^{[1
,2
]}

Wei, Qiang ^{[1
,2
]}

Bao, Linlin ^{[1
,2
]}

机构：

[1] Chinese Acad Med Sci, NHC Key Lab Human Dis Comparat Med, Beijing Key Lab Anim Models Emerging & Remerging, Inst Lab Anim Sci, Beijing, Peoples R China

[2] Peking Union Med Coll, Comparat Med Ctr, Beijing, Peoples R China

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2020年 / 5卷 / 01期

关键词：

D O I：

10.1038/s41392-020-0176-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页数：3

共 5 条

[1]

Bao L., 2020, PATHOGENICITY SARS C, DOI DOI 10.1101/2020.02.07.939389V1

[2] Pudilan xiaoyan oral liquid alleviates LPS-induced respiratory injury through decreasing nitroxidative stress and blocking TLR4 activation along with NF-KB phosphorylation in mice [J].

Feng, Liang ;

Yang, Nan ;

Li, Chao ;

Tian, Gang ;

Wang, Jing ;

Dong, Zi-Bo ;

Jia, Xiao-Bin ;

Di, Liu-Qing .

JOURNAL OF ETHNOPHARMACOLOGY, 2018, 214 :292-300

[3]

Li G., 2020, NAT REV DRUG DISCOV, DOI [10.1038/ d41573- 41020- 00016-41570, DOI 10.1038/D41573-41020-00016-41570, 10.1038/d41573-41020-00016-41570]

[4] GC-MS based metabolomic profiling of lung tissue couple with network pharmacology revealed the possible protection mechanism of Pudilan Xiaoyan Oral Liquid in LPS-induced lung injury of mice [J].

Tian, Gang ;

Li, Chao ;

Zhai, Yuanyuan ;

Xu, Jia ;

Feng, Li ;

Yao, Weifeng ;

Bao, Beihua ;

Zhang, Li ;

Ding, Anwei .

BIOMEDICINE & PHARMACOTHERAPY, 2020, 124

[5] Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [J].

Wang, Manli ;

Cao, Ruiyuan ;

Zhang, Leike ;

Yang, Xinglou ;

Liu, Jia ;

Xu, Mingyue ;

Shi, Zhengli ;

Hu, Zhihong ;

Zhong, Wu ;

Xiao, Gengfu .

CELL RESEARCH, 2020, 30 (03) :269-271

← 1 →